Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19554326 | 0.86 | KDM4E (0.51) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL1965781 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL31634578 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL1931203 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL6109360 | 0.84 | GAA (0.66) | ALDH1A1KDM4EHPGDGAAHTT | |
| SCHEMBL9706363 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL3423769 | 0.83 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL16401736 | 0.82 | HTR4 (0.48) | ALDH1A1KDM4EGAALMNAHTT | |
| SCHEMBL22691985 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDLCKFYN | |
| SCHEMBL22987079 | 0.81 | TSHR (0.53) | ALDH1A1KDM4EHPGDGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1233240-A | Synthesis method of cisapride | JANSSEN PHARMACEUTICA NV (BE) | 1999-10-27 | — | — | CN | claimed |
| EP-4658658-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2025-12-10 | — | — | EP | disclosed |
| CN-119790057-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2025-04-08 | — | — | CN | disclosed |
| US-20240417393-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | US | disclosed |
| EP-4412707-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024162828-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2024-08-08 | — | — | WO | disclosed |
| CN-118103366-A | Certain 2, 5-diazabicyclo [4.2.0] octanes as GLP-1 receptor modulators | 阿斯利康(瑞典)有限公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2023057427-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2023-04-13 | — | — | WO | disclosed |
| EP-3586838-B1 | AMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-10925848-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-23 | — | — | US | disclosed |
| US-9643961-B2 | Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2017-05-09 | — | — | US | disclosed |
| EP-2569308-B1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING BETA2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL SA (ES) | 2016-11-23 | — | — | EP | disclosed |
| US-20160264557-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2016-09-15 | — | — | US | disclosed |
| US-20160122300-A1 | ACETYLCHOLINESTERASE INHIBITOR COMPOUNDS AND 5HT4 SEROTONERGIC RECEPTOR AGONISTS, WITH PROMNSIA EFFECT, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | UNIVERSITE DE CAEN (FR) | 2016-05-05 | — | — | US | disclosed |
| US-9315463-B2 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities | ALMIRALL, S.A. (ES) | 2016-04-19 | — | — | US | disclosed |
| US-20130281415-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2013-10-24 | — | — | US | disclosed |
| EP-2569308-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING 2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | Almirall S.A. (ES) | 2013-03-20 | — | — | EP | disclosed |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | PRAT QUINONES MARIA (ES) | 2013-02-28 | — | — | US | disclosed |
| WO-2011141180-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ALMIRALL, S.A. (ES) | 2011-11-17 | — | — | WO | disclosed |
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264557-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | ALDH1A1 1707/4885KDM4E 3592/4885HPGD 2212/4885 |
| US-10925848-B2 | Amide derivative | IDO1, IDO2, TPH1 | ALDH1A1 750/4885KDM4E 2941/4885HPGD 550/4885 |
| US-20130281415-A9 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING ß2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | ALDH1A1 1849/4885KDM4E 3728/4885HPGD 2389/4885 |
| US-20160122300-A1 | ACETYLCHOLINESTERASE INHIBITOR COMPOUNDS AND 5HT4 SEROTONERGIC RECEPTOR AGONISTS, WITH PROMNSIA EFFECT, METHODS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR4, CHRNA4, CHRNB4 | ALDH1A1 781/4885KDM4E 1600/4885HPGD 1304/4885 |
| US-20130053359-A1 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING beta2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES | ADRB2, CHRM2, CHRM3 | ALDH1A1 1932/4885KDM4E 3836/4885HPGD 2309/4885 |
| US-20240417393-A1 | CERTAIN 2,5-DIAZABICYCLO[4.2.0]OCTANES AS GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, GPR119 | ALDH1A1 1404/4885KDM4E 2600/4885HPGD 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.